Table 3 Clinical features of patients randomized to the three different detoxification groups at follow-up visits
From: Treatment of withdrawal headache in patients with medication overuse headache: a pilot study
Total | Withdrawal therapy groups | |||||
|---|---|---|---|---|---|---|
A:Methylprednisolone | B:Paracetamol | C:Placebo | p value | |||
Sample | N (%) | 53 | 18 | 19 | 16 | |
Headache frequency | ||||||
< 15 days T4 | N (%) | 28 (52.8) | 9 (50.0) | 8 (42.1) | 11 (68.7) | 0.481 |
≥ 15 days at T3 | N (%) | 20 (37.8) | 8 (44.4) | 8 (42.1) | 4 (25.0) | |
≥ 15 days at T4 | N (%) | 5 (9.4) | 1 (5.6) | 3 (15.8) | 1 (6.3) | |
Medication overused after detoxification | ||||||
< 15 days T3 | N (%) | 33 (62.3) | 11 (61.1) | 9 (47.4) | 13 (81.2) | 0.216 |
≥ 15 days at T3 | N (%) | 14 (26.4) | 6 (33.3) | 6 (31.6) | 2 (12.5) | |
≥ 15 days at T4 | N (%) | 6 (11.3) | 1 (5.6) | 4 (21.0) | 1 (6.3) | |
Headache frequency T3 (days/month) | med; IQR | 13.5; 8–24 | 14.5; 7–26 | 17; 9.5–24 | 10; 7.5–17 | 0.428 |
Headache frequency T4 (days/month) | med; IQR | 13.5; 7–20 | 14; 4–26 | 17; 7–20 | 12; 7–18 | 0.735 |
Frequency of Medication Intake T3 (days/month) | med; IQR | 8; 5–13 | 8; 4–14 | 8.5; 6–17 | 7.5; 4–9.5 | 0.438 |
Frequency of Medication Intake T4 (days/month) | med; IQR | 9.5; 4.5–13 | 10.5; 4–15 | 10; 5–14 | 9; 7–10 | 0.851 |